New Delhi: Drug firm Zydus Cadila has received approval from the US health regulator to market its generic Doxycycline capsules used for the treatment of bacterial infections in the American market.
"Zydus Cadila has received approval from the United States Food and Drug Administration (USFDA) to market Doxycycline capsules USP, 50 mg, 75 mg, and 100 mg," Cadila Healthcare said in a BSE filing.
The drug falls in the anti-bacterials segment, it added.
"With this first approval, the group will now commence supplies to the US market from its formulation manufacturing facility located at the SEZ in Ahmedabad," Cadila Healthcare said.
The group now has 102 approvals and has so far filed over 280 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04, it added.
Shares of Cadila Healthcare closed at Rs 327.2 on BSE, up 1.55 per cent from the previous close.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
